Moreover, FASN inhibitors can block palmitoylation and plasma membrane- and mitochondria-associated EGFR activation and enhance cancer cell sensitivity to EGFR inhibitors by promoting EGFR ubiquitination, which further results in attenuating tumor growth (33, 34). Here, EGFR is linked to cancer.